Ann: Q&A on the merger of QBL MCL and Medcan, page-114

I notice that those who post comments which are of a negative nature get blasted. This forum is for all to post and there are different views expressed, some of which have merit. There was an expectation that when the trading was suspended and an announcement was forthcoming, that the announcement would lift the prices to unprecedented heights. This was not the case and the price is now back to where it was previously. There is a lot of disappointment and this is not unusual. This company is now unique in that it has two seperate businesses which are completely different for each other and the task to develop both is not an easy one. The cost of acquiring the two companies is a bone of contention in that many feel that the price s paid are far too much and there is now the question of dilution. The CE tried to explain the decisions made but I must say I was far from being convinced. I recall not to long ago shareholders were advised that a team was in China in negotiations with some interested parties on the bauxite operations. Nothing has been mentioned about this to date. Did negotiations fail? I do believe that funding is going to be a problem and the current cash position of the company is insufficient to realise its goals and even if the rights are taken up it is not a big amount. What it needs is to have a revenue stream to finance its proposed operations and when the bauxite and/or cannabis ventures start generating a steady cash flow we will then see the light. Management has not been clear on timelines and projections to generate any confidence in the company and this is why the sp is at present levels.